Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 10:02 am Sale | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | Menora Mivtachim Holdings Ltd | 2,303,031 7.460% | -615,971 (-21.10%) | Filing History |
| 2024-02-14 10:01 am Sale | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | Stonepine Capital Management, LLC | 0 0.000% | -1,304,947 (Position Closed) | Filing History |
| 2024-02-14 07:07 am Purchase | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | RTW Investments, LP | 1,726,808 5.600% | 1,726,808 (New Position) | Filing History |
| 2024-02-02 2:18 pm Purchase | 2023-12-31 | 13G | UroGen Pharma Ltd. URGN | BlackRock Inc. BLK | 1,719,304 5.600% | 1,378,892 (+405.07%) | Filing |
| 2023-12-29 4:30 pm Purchase | 2023-12-19 | 13G | UroGen Pharma Ltd. URGN | RA Capital Management, L.P. | 3,083,550 9.990% | 3,083,550 (New Position) | Filing History |
| 2023-09-15 1:39 pm Purchase | 2023-09-08 | 13G | UroGen Pharma Ltd. URGN | Great Point Partners, LLC | 2,620,545 8.510% | 2,620,545 (New Position) | Filing History |
| 2023-08-04 08:56 am Purchase | 2023-07-26 | 13D | UroGen Pharma Ltd. URGN | Monograph Capital Holdings Advisors LLC | 1,662,327 5.400% | 1,662,327 (New Position) | Filing History |
| 2023-06-12 08:47 am Sale | 2023-06-12 | 13G | UroGen Pharma Ltd. URGN | Menora Mivtachim Holdings Ltd | 2,919,002 12.450% | -35,697 (-1.21%) | Filing History |
| 2023-02-13 10:57 am Purchase | 2022-12-31 | 13G | UroGen Pharma Ltd. URGN | Stonepine Capital Management, LLC | 1,304,947 5.700% | 108,039 (+9.03%) | Filing History |
| 2022-12-02 11:15 am Purchase | 2022-11-22 | 13G | UroGen Pharma Ltd. URGN | Stonepine Capital Management, LLC | 1,196,908 5.200% | 1,196,908 (New Position) | Filing History |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | UroGen Pharma Ltd. URGN | BlackRock Inc. BLK | 340,412 1.500% | -1,387,682 (-80.30%) | Filing |
| 2022-02-14 4:15 pm Sale | 2021-12-31 | 13G | UroGen Pharma Ltd. URGN | Wildcat Capital Management, LLC | 533,139 2.400% | -719,146 (-57.43%) | Filing History |
| 2022-02-14 1:44 pm Sale | 2021-12-31 | 13G | UroGen Pharma Ltd. URGN | CREDIT SUISSE AG | 1,085,749 4.840% | -35,322 (-3.15%) | Filing History |
| 2022-02-04 09:12 am Sale | 2021-12-31 | 13G | UroGen Pharma Ltd. URGN | WELLINGTON MANAGEMENT GROUP LLP | 238,008 1.060% | -1,602,629 (-87.07%) | Filing History |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | UroGen Pharma Ltd. URGN | BlackRock Inc. BLK | 1,728,094 7.700% | 198,603 (+12.98%) | Filing |
| 2021-02-12 4:10 pm Purchase | 2020-12-31 | 13G | UroGen Pharma Ltd. URGN | Wildcat Capital Management, LLC | 1,252,285 5.670% | 96,423 (+8.34%) | Filing History |
| 2021-02-12 4:03 pm Purchase | 2020-12-31 | 13G | UroGen Pharma Ltd. URGN | CREDIT SUISSE AG | 1,121,071 5.070% | 1,121,071 (New Position) | Filing History |
| 2021-02-11 07:28 am Unchanged | 2020-12-31 | 13G | UroGen Pharma Ltd. URGN | Menora Mivtachim Holdings Ltd | 2,954,699 13.370% | 0 (Unchanged) | Filing History |
| 2021-02-03 1:13 pm Purchase | 2020-12-31 | 13G | UroGen Pharma Ltd. URGN | WELLINGTON MANAGEMENT GROUP LLP | 1,840,637 8.330% | 550,040 (+42.62%) | Filing History |
| 2021-02-01 08:17 am Purchase | 2020-12-31 | 13G | UroGen Pharma Ltd. URGN | BlackRock Inc. BLK | 1,529,491 6.900% | 156,628 (+11.41%) | Filing |